Literature DB >> 15848274

Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees.

Kendra M Viner1, Stuart N Isaacs.   

Abstract

Individuals vaccinated against smallpox maintain substantial antiviral antibody responses for many years after vaccination. In this study, we examined the ability of antiviral antibodies from 104 unique serum samples to neutralize the two infectious forms of vaccinia virus, intracellular mature virus (IMV) and extracellular enveloped virus (EEV). While we found direct correlations between antiviral antibody titers and the ability to neutralize IMV and EEV, correlation with EEV neutralization was weaker. To determine factors that may influence more varied EEV neutralization within a vaccinated population, we asked the following questions. (1) Does vaccinia virus-neutralizing ability remain constant over time? (2) Do multiple vaccinations boost IMV and EEV neutralization activity? We found that serum from vaccinated individuals retained ability to neutralize EEV for a relatively long time, but there was a significant drop in EEV neutralization ability in the third decade after vaccination. While all vaccinees maintained some ability to neutralize IMV, a number of individuals lost the capacity to neutralize EEV. Interestingly, the ability to neutralize either virus form was not altered by the number of vaccinations received. Since it is likely that neutralizing antibodies against both IMV and EEV are required for maximal protective immunity, a loss of anti-EEV-neutralizing ability may warrant the revaccination of individuals who have been vaccinated >20 years ago, should widespread pre-event smallpox vaccination be instituted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848274     DOI: 10.1016/j.micinf.2005.02.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  23 in total

1.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

2.  Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus.

Authors:  Xiangzhi Meng; Youmin Zhong; Addie Embry; Bo Yan; Shan Lu; Guangming Zhong; Yan Xiang
Journal:  Virology       Date:  2010-11-05       Impact factor: 3.616

3.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

4.  B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.

Authors:  Kendra M Viner; Natasha Girgis; Heesun Kwak; Stuart N Isaacs
Journal:  Virology       Date:  2006-12-26       Impact factor: 3.616

5.  The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Authors:  Natasha M Girgis; Brian C Dehaven; Yuhong Xiao; Edward Alexander; Kendra M Viner; Stuart N Isaacs
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

6.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

7.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

8.  Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Authors:  Richard Kennedy; V Shane Pankratz; Eric Swanson; David Watson; Hana Golding; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2009-06-17

9.  Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

Authors:  Alonzo D García; Clement A Meseda; Anne E Mayer; Arunima Kumar; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling.

Authors:  Lichen Jing; D Huw Davies; Tiana M Chong; Sookhee Chun; Christopher L McClurkan; Jay Huang; Brian T Story; Douglas M Molina; Siddiqua Hirst; Philip L Felgner; David M Koelle
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.